Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis

Abstract

Objective To investigate the effect of the mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis. Methods A total of 24 adult male C57BL/6J mice were randomly divided into control group, control+SS-31 group, lipopolysaccharide (LPS) group, and LPS+SS-31 group, with 6 mice in each group. The mice were given intraperitoneal injection of LPS (10 mg/kg) to establish a model of sepsis and acute liver injury, followed by intraperitoneal injection of SS-31 (10 mg/kg) for treatment, and the mice in the control group were given intraperitoneal injection of an equal volume of PBS solution, followed by intraperitoneal injection of an equal volume of normal saline. After 12 hours, ELISA was used to measure the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), reactive oxygen species (ROS), superoxide dismutase (SOD), tumor necrosis factor-α (TNFα), interleukin-1β(IL-1β), and interleukin-6 (IL-6), and HE staining was used to observe liver histopathological changes. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results Compared with the LPS group, the LPS+SS-31 group had significant reductions in the serum levels of ALT (140.05±12.22 U/L vs 102.64±8.75 U/L, P < 0.05) and AST (80.22±4.71 U/L vs 69.26±5.37 U/L, P < 0.05) and the levels of ROS (1 030.21±115.87 pg/mL vs 847.84±63.65 pg/mL, P < 0.05), TNFα (767.18±60.60 ng/mL vs 698.89±16.99 ng/mL, P < 0.05), IL-1β (29.97±1.37 ng/mL vs 26.70±3.09 ng/mL, P < 0.05), and IL-6 (59.13±7.09 pg/mL vs 49.29±3.41 pg/mL, P < 0.05) in liver tissue. Compared with the control group based on HE staining, the LPS group showed destruction of hepatic lobular structure, inflammatory cell infiltration, ambiguous intercellular space, and hepatocyte swelling, while the LPS+SS-31 group showed alleviation of inflammatory cell infiltration and hepatocyte swelling. Conclusion The mitochondria-targeted antioxidant SS-31 can reduce the production of ROS, downregulate the highly expressed inflammatory factors in sepsis, and alleviate sepsis-related acute liver injury in mice.
- Liver Diseases,
- Antioxidants,
- Sepsis,
- Mice, Inbred C57BL

FullText(HTML)

References(21)

References

[1]	SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. DOI: 10.1001/jama.2016.0287.
[2]	FLEISCHMANN C, SCHERAG A, ADHIKARI NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations[J]. Am J Respir Crit Care Med, 2016, 193(3): 259-272. DOI: 10.1164/rccm.201504-0781OC.
[3]	WANG L, QIU YL, WANG JS. Advances in research and application of liver organoids[J]. J Clin Hepatol, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047. 王利, 丘倚灵, 王建设. 肝类器官研究及应用进展[J]. 临床肝胆病杂志, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047.
[4]	WANG DD, SONG J, ZHANG XL. Research advances in the role of gut microbiota in liver diseases[J]. J Clin Hepatol, 2019, 35(9): 2120-2123. DOI: 10.3969/j.issn.1001-5256.2019.09.053. 王丹丹, 宋佳, 张晓岚. 肠道菌群在肝脏疾病中的作用[J]. 临床肝胆病杂志, 2019, 35(9): 2120-2123. DOI: 10.3969/j.issn.1001-5256.2019.09.053.
[5]	XING BM, GUO N, NING HH, et al. Sepsis liver damage and autophagy[J/CD]. Chin J Liver Dis (Electronic Version), 2021, 13(3): 37-41. DOI: 10.3969/j.issn.1674-7380.2021.03.006. 邢博民, 郭娜, 宁海慧, 等. 脓毒症肝损伤与自噬[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(3): 37-41. DOI: 10.3969/j.issn.1674-7380.2021.03.006.
[6]	KOBASHI H, TOSHIMORI J, YAMAMOTO K. Sepsis-associated liver injury: Incidence, classification and the clinical significance[J]. Hepatol Res, 2013, 43(3): 255-266. DOI: 10.1111/j.1872-034X.2012.01069.x.
[7]	MARSHALL JC. New translational research provides insights into liver dysfunction in sepsis[J]. PLoS Med, 2012, 9(11): e1001341. DOI: 10.1371/journal.pmed.1001341.
[8]	FUCHS M, SANYAL AJ. Sepsis and cholestasis[J]. Clin Liver Dis, 2008, 12(1): 151-172, ix. DOI: 10.1016/j.cld.2007.11.002.
[9]	CHIAO YA, ZHANG H, SWEETWYNE M, et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice[J]. Elife, 2020, 9: e55513. DOI: 10.7554/eLife.55513.
[10]	YANG L, ZHAO K, CALINGASAN NY, et al. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity[J]. Antioxid Redox Signal, 2009, 11(9): 2095-2104. DOI: 10.1089/ars.2009.2445.
[11]	TALBERT EE, SMUDER AJ, MIN K, et al. Immobilization-induced activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted antioxidant[J]. J Appl Physiol (1985), 2013, 115(4): 529-538. DOI: 10.1152/japplphysiol.00471.2013.
[12]	SZETO HH, LIU S, SOONG Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury[J]. J Am Soc Nephrol, 2011, 22(6): 1041-1052. DOI: 10.1681/ASN.2010080808.
[13]	WU J, HAO S, SUN XR, et al. Elamipretide (SS-31) ameliorates isoflurane-induced long-term impairments of mitochondrial morphogenesis and cognition in developing rats[J]. Front Cell Neurosci, 2017, 11: 119. DOI: 10.3389/fncel.2017.00119.
[14]	ALLEN ME, PENNINGTON ER, PERRY JB, et al. The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats[J]. Commun Biol, 2020, 3(1): 389. DOI: 10.1038/s42003-020-1101-3.
[15]	ZHANG XT, LIU JZ, LI P, et al. Research progress of mitophagy in sepsis[J]. China Med Herald, 2021, 18(10): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202110011.htm 张欣桐, 刘景卓, 李盼, 等. 线粒体自噬在脓毒症中的研究进展[J]. 中国医药导报, 2021, 18(10): 39-42. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202110011.htm
[16]	SUN XD, YAN YH, ZHANG YT, et al. Effects of Xuebijing injection on oxidative stress and early inflammatory factors in rats with sepsis induced liver injury[J]. Chin J Mod Appl Pharm, 2016, 33(10): 1255-1259. DOI: 10.13748/j.cnki.issn1007-7693.2016.10.008. 孙雪东, 严一核, 张亦婷, 等. 血必净对脓毒症肝损伤大鼠氧化应激及炎症状态的影响[J]. 中国现代应用药学, 2016, 33(10): 1255-1259. DOI: 10.13748/j.cnki.issn1007-7693.2016.10.008.
[17]	ZHAO W, XU Z, CAO J, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice[J]. J Neuroinflammation, 2019, 16(1): 230. DOI: 10.1186/s12974-019-1627-9.
[18]	SMUDER AJ, ROBERTS BM, WIGGS MP, et al. Pharmacological targeting of mitochondrial function and reactive oxygen species production prevents colon 26 cancer-induced cardiorespiratory muscle weakness[J]. Oncotarget, 2020, 11(38): 3502-3514. DOI: 10.18632/oncotarget.27748.
[19]	HAO ZH, HUANG Y, WANG MR, et al. SS31 ameliorates age-related activation of NF-κB signaling in senile mice model, SAMP8[J]. Oncotarget, 2017, 8(2): 1983-1992. DOI: 10.18632/oncotarget.14077.
[20]	BUTLER J, KHAN MS, ANKER SD, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial[J]. J Card Fail, 2020, 26(5): 429-437. DOI: 10.1016/j.cardfail.2020.02.001.
[21]	KARAA A, HAAS R, GOLDSTEIN A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy[J]. Neurology, 2018, 90(14): e1212-e1221. DOI: 10.1212/WNL.0000000000005255.

Relative Articles

[1]	Xin DAI, Hanlin LIU, Long CHENG, Zhulin LUO, Tao WANG. Association of programmed death-1 and programmed death-ligand 1 with the prognosis and clinical features of patients with hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2022.07.022
[2]	Pan LIU, Liang HAO, Yu CHENG, Beibei YANG, Yong WEI, Zhenhong XIA, Shoujun YU. Advances in the application of ultrasound in the diagnosis and treatment of acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2873-2876. doi: 10.3969/j.issn.1001-5256.2022.12.037
[3]	Xiangliu OUYANG, Yunxia HAN, Lichun ZHENG, Yingchun ZHAO, Xinyu SHEN, Wenjun ZHANG, Yanbin WANG. Ultrasound findings and contrast-enhanced ultrasound findings of mass-type autoimmune pancreatitis versus pancreatic ductal adenocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1351-1355. doi: 10.3969/j.issn.1001-5256.2022.06.025
[4]	Quan ZHOU, Lihui YANG, Fangqing JIANG. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1836-1840. doi: 10.3969/j.issn.1001-5256.2021.08.018
[5]	Minjun LI, Zhujian DENG, Haotian LIU, Yuxian TENG, Rongrui HUO, Xiumei LIANG, Bangde XIANG, Lequn LI, Jianhong ZHONG. Clinical effect of re-hepatic resection versus radiofrequency ablation in treatment of recurrent hepatocellular carcinoma in Asia: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1103-1109. doi: 10.3969/j.issn.1001-5256.2021.05.025
[6]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[7]	Ying LIU, Benjian GAO, Xiaoli YANG, Cheng FANG, Song SU, Bo LI. Effect of hemihepatic vascular exclusion versus total hepatic vascular exclusion in hepatectomy for primary liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(1): 73-78. doi: 10.3969/j.issn.1001-5256.2021.01.015
[8]	Shun ZHU, Zhiguo LI, Shuo LI, Xu CAO, Xiaobin LI, Xiaoke LI, Yongan YE. Effect of aspirin on the incidence rate of liver cancer in patients with viral hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(5): 1097-1102. doi: 10.3969/j.issn.1001-5256.2021.05.024
[9]	Sun DongXue, Yang Zhu, Long FengXi, Wei XianMan, Tang DongXin. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 363-368. doi: 10.3969/j.issn.1001-5256.2020.02.026
[10]	Qian Le, Ying Li. Selection of second-line drugs for adult autoimmune hepatitis: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2015-2020. doi: 10.3969/j.issn.1001-5256.2020.09.021
[11]	Zhou ZiDong, Li RenLi, Chen Kai, Zhang WenCheng, Xia ShiHai. Clinical effect of epidermal growth factor receptor-targeted agents in treatment of advanced pancreatic cancer:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(5): 1097-1103. doi: 10.3969/j.issn.1001-5256.2020.05.029
[12]	Zi Li, Chen Kai, Liu GuangLin, Li RenLi, Xu Wei. Clinical effect of gemcitabine combined with high-intensity focused ultrasound in treatment of advanced pancreatic cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(1): 153-157. doi: 10.3969/j.issn.1001-5256.2020.01.034
[13]	Li Dong, Luo TianYang, Ran YaWei. Value of contrast-enhanced computed tomography and magnetic resonance imaging in diagnosis of residual or recurrent lesion after transcatheter arterial chemoembolization in hepatocellular carcinoma:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2214-2219. doi: 10.3969/j.issn.1001-5256.2019.10.017
[14]	Wang YiBin, Liao JinTang, Xie LuLu, Qi WenJun, Chen LuYang, Li YueYi. Predictive value of preoperative ultrasound examination for factors associated with early postoperative recurrence of hepatocellular carcinoma after surgical resection [J]. Journal of Clinical Hepatology, 2015, 31(12): 2061-2065. doi: 10.3969/j.issn.1001-5256.2015.12.018
[15]	Liu LingFeng, Lu HaiYing, Yu YanYan, Wu ChiHong, Tian XiuLan. A comparative study of FibroScan and B ultrasound in diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(10): 1045-1049. doi: 10.3969/j.issn.1001-5256.2014.10.018
[16]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the management of pancreatic cancer (2014)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1240-1245. doi: 10.3969/j.issn.1001-5256.2014.12.003
[17]	Li ChunSheng, Ni CanRong. Expression of S100A4 and E-cadherin in pancreatic carcinoma and their relationship study[J]. Journal of Clinical Hepatology, 2006, 22(3): 207-208.
[18]	Ren Ben, Song JiangBo, Zhang FenQin, Si HongXia, Gao XuanXia. Stereotactic radiotherapy in 206 patients with pancreatic carcinoma[J]. Journal of Clinical Hepatology, 2006, 22(1): 52-53.
[20]	Yuan ZhangJi, Yang Lei, Yao Cheng, Wang GuanJun. Observation of high intensity focused ultrasound treating 40 cases of cancer of pancreas[J]. Journal of Clinical Hepatology, 2003, 19(3): 145-146.

Supplements(0)

Cited By

Cited by

Periodical cited type(37)

1.	李容容，苟悦，刘宁宁，陈日润，孙鑫，刘成海. 基于临床数据挖掘的中药对抗肿瘤药物相关肝损伤的影响及用药规律探讨. 时珍国医国药. 2024(01): 243-247 .
2.	张倩茹，卢颖，张婉婷，杨艳. 某院急性白血病患者药源性肝损伤临床治疗的回顾性分析. 遵义医科大学学报. 2024(04): 401-407 .
3.	中华医学会，中华医学会杂志社，中华医学会肝病分会药物性肝病学组，中华医学会全科医学分会，中华医学会《中华全科医师杂志》编辑委员会，中国医药生物技术协会药物性肝损伤防治技术专业委员会，中国初级卫生保健基金会药物肝脏安全性专业委员会，中国药物性肝损伤基层诊疗与管理指南制定专家组. 中国药物性肝损伤基层诊疗与管理指南(2024年). 中华全科医师杂志. 2024(08): 813-830 .
4.	郑晖，孙蓉. 药物联合应用对中草药相关肝损伤的影响. 临床肝胆病杂志. 2024(08): 1519-1524 . 本站查看
5.	李容容，李盟，苟悦，罗琼，吕桦，孙鑫，刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析. 中国药物警戒. 2023(05): 505-510 .
6.	中国医药生物技术协会药物性肝损伤防治技术专业委员会，中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版). 中华肝脏病杂志. 2023(04): 355-384 .
7.	程诗思，杨成明，曾安津. 荆州地区结核病专科医院抗结核药物不良反应分析. 临床合理用药. 2023(22): 147-150 .
8.	江程，李春晓，杨玉晴，郭静. 热毒宁注射液上市后临床安全性文献研究. 中国药事. 2023(11): 1252-1265 .
9.	王双双，熊清芳，胡一帆，陈妙洋，杨永峰. 药物性肝损伤的临床与病理特点分析. 肝脏. 2023(11): 1280-1284 .
10.	孟尧，张萌萌，郭甜甜，赵新颜. 《中国药物性肝损伤诊治指南（2023年版）》更新要点解读. 中国肝脏病杂志(电子版). 2023(04): 1-5 .
11.	马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2023(07): 397-431 .
12.	孙晓楠，吕萌，程国亭. 药物性肝损伤139例回顾性分析. 中南医学科学杂志. 2022(03): 391-394 .
13.	李娜. 肺癌患者化疗后药物性肝损伤的临床特点. 中国医药指南. 2022(16): 22-25 .
14.	劳明珠. 异甘草酸镁治疗抗肿瘤药物引起的急性药物性肝损伤临床效果和安全性. 临床合理用药杂志. 2022(17): 84-87 .
15.	马万龙，焦运，张旭，丁向春，张平，欧阳花，王梦甜，张乐，徐灵博，杨安宁，姜怡邓. 血清IL-6在人工肝治疗药物性肝损伤预后评估中的价值. 宁夏医科大学学报. 2022(06): 622-629 .
16.	沈婷婷，李光耀，罗琼，李盟，孙鑫，陶艳艳，周祖山，刘成海. 类风湿性关节炎患者应用雷公藤制剂及合并用药所致药物性肝损伤的临床特征分析. 临床肝胆病杂志. 2022(09): 2067-2072 . 本站查看
17.	马世武，刘成海，刘晓琰，苏明华，李东良，李异玲，陈公英，陈军，陈金军，茅益民，赵景民，郭晓燕，唐洁婷，诸葛宇征，谢青，谢雯，赖荣陶，蔡大川，蔡庆贤. 中国药物性肝损伤诊治指南（2023年版）. 胃肠病学. 2022(06): 341-375 .
18.	汪涛，王学伟，蒋元烨，曹勤，季光. 162例药物性肝损伤患者分析. 肝脏. 2021(03): 243-246 .
19.	王艳，王昱，王岚，田秋菊，杨瑞园，李柯鑫，刘立伟，王晓明，王宇，欧晓娟，贾继东，赵新颜. 中草药与西药致药物性肝损伤的临床特征及其预后的对比研究. 肝脏. 2021(04): 364-369 .
20.	杨焕芝，李兴德，陈学平，张仲安，钱彦华，蒋潇，徐艳琼，宋沧桑. 93例药物性肝损伤患者临床特征分析. 中国药业. 2021(15): 122-125 .
21.	何婷婷，王丽苹，任璐彤，崔延飞，柏兆方，郭玉明，宫嫚，王睿林. 中西药肝损伤临床及病理特征分析. 肝脏. 2021(09): 962-967 .
22.	刘秀兰，李为，郭敏，杜金凤，刘东，李娟. 药物性肝损伤相关医疗损害案例分析. 药物流行病学杂志. 2021(11): 729-734 .
23.	陈凯霞，赵广玉，印登阳，陈宏俊，黄继勋. 三种保肝药治疗化疗引起的DILI的药物经济学评价. 中国实用医药. 2021(35): 188-191 .
24.	罗琼，朱哿瑞，顾宏图，刘坤，陈高峰，邢枫，陶艳艳，刘成海. 50例中草药与西药致药物性肝损伤患者的肝组织病理学特点比较. 临床肝胆病杂志. 2020(03): 596-601 . 本站查看
25.	蔡春梅. 妊娠早期肝功能异常60例的病因分析及干预. 中国城乡企业卫生. 2020(06): 100-102 .
26.	周力. 中西药所致药物性肝损伤临床及病理特点研究. 临床医药文献电子杂志. 2020(39): 56 .
27.	纪童童，陆海英，谭宁，于岩岩，徐小元. 急、慢性药物性肝损伤临床特征的对比分析. 临床肝胆病杂志. 2020(07): 1556-1561 . 本站查看
28.	何文昌，张克恭，赵凡惠，郭芮杉，高禄化，黄长形，王临旭. 290例药物性肝损伤患者临床特征分析. 实用肝脏病杂志. 2020(04): 540-543 .
29.	李梁，陶应敏，张学敏，谢娟，陈园. 药物性肝损伤患者外周血清HIF1α和COX-2定量检测的临床价值. 肝脏. 2020(08): 848-852 .
30.	李卉，张宏亮，杨天燕，黄振光，刘滔滔，韦芳. 我院125例抗结核药物不良反应报告分析. 中国医药导报. 2020(29): 151-154 .
31.	姜正艳，郑亮. 异甘草酸镁治疗药物性肝损伤临床疗效观察. 世界最新医学信息文摘. 2019(07): 123 .
32.	张惠娟，史祖宣，赵兰芳，高天慧，李健. 56例抗肿瘤药物致肝损伤临床特点分析. 临床肝胆病杂志. 2019(03): 574-578 . 本站查看
33.	梁栋，董晓锋，张燕，朱晓红，王建斌，刘妲妲，柳伟伟，方圆，王全楚. 98例药物性肝损伤的临床特点及诊疗体会. 肝脏. 2019(04): 389-391 .
34.	黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 .
35.	郭立杰，张海丛，叶立红，王超，杜婧，伍彦辉. 中西药所致药物性肝损伤临床及病理特点分析. 临床误诊误治. 2019(08): 28-33 .
36.	吴宇宇，袁苏榆，孙四珍，王岁晶，丁洋. 药物性肝损伤诊断治疗进展概述. 药物流行病学杂志. 2018(08): 550-555 .
37.	王建青，叶珺，郜玉峰，杨利琦. 106例药物性肝损伤患者用药回顾性调查. 中国医院药学杂志. 2018(18): 1967-1970 .

Other cited types(11)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (1126) PDF downloads(58)

Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis

DOI: 10.3969/j.issn.1001-5256.2022.02.025